<DOC>
	<DOCNO>NCT00002544</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know mitoxantrone effective without docetaxel . PURPOSE : Randomized phase III trial compare effectiveness mitoxantrone without docetaxel treat woman metastatic breast cancer poor prognosis .</brief_summary>
	<brief_title>Mitoxantrone With Without Docetaxel Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival quality life score ( composed time progression , WHO performance status , subjective patient evaluation , subjective adverse event profile ) among woman metastatic breast cancer unfavorable prognosis treat mitoxantrone v mitoxantrone plus docetaxel first-line chemotherapy metastatic disease . - Compare remission rate , time remission , remission duration , time best response , objective adverse event , patient acceptance treatment 2 regimen . - Investigate prognostic subgroup woman benefit treatment . OUTLINE : This randomize , multicenter study . Patients stratify accord age , treatment center , disease free interval ( 18 month vs 18 month ) , hormone receptor status ( positive unknown v negative ) , prior adjuvant therapy anthracyclines ( yes v ) , presence liver metastasis ( liver involvement single organ v liver plus organ involvement v liver involvement ) , presence lung metastasis ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive mitoxantrone IV day 1 . Treatment repeat every 3 week disease progression , unacceptable toxicity , maximum cumulative dose . Patients achieve complete response receive 2 additional course . - Arm II : Patients receive mitoxantrone IV plus docetaxel IV 1 hour day 1 . Treatment repeat every 3 week maximum 6 course absence disease progression unacceptable toxicity . At relapse , reinduction original regimen attempt . Following second complete response , 2 additional course consolidative treatment give , patient follow treatment . Quality life assess periodically . PROJECTED ACCRUAL : A total 300 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic breast cancer poor prognosis , define follow characteristic : Patient age 35 Liver metastasis Lung metastasis combine disease manifestation Lung metastases without disease manifestation disease free interval 18 month Indication chemotherapy document either : Hormone receptor negativity OR Hormone resistant disease Measurable metastatic disease require Nonmeasurable disease include : Metastases verify histologically Tumor parameter precisely measurable ( e.g. , bone marrow involvement , lymphangitic disease ) No CNS metastasis bone marrow carcinomatosis Hormone receptor status : Receptor status know PATIENT CHARACTERISTICS : Age : 80 Sex : Female Menopausal status : Not specify Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : WBC great 4,000/mm^3 Absolute granulocyte count great 2,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) Alkaline phosphatase great 6 time ULN SGOT and/or SGPT great 3 time ULN Renal : Creatinine great 1.15 time ULN Cardiovascular : No uncontrolled hypertension No congestive heart failure within past 6 month No myocardial infarction within past 6 month Other : Fertile patient must use effective contraception No acute chronic infection No second primary tumor No serious illness PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : No prior chemotherapy metastatic disease Greater 1 year since prior adjuvant chemotherapy No prior anthracycline anthraquinone Endocrine therapy : Hormone resistant disease require receptor positive patient No concurrent endocrine therapy Radiotherapy : No prior mediastinal irradiation Adjuvant irradiation parasternal node eligible No prior irradiation 25 % bone marrow No concurrent irradiation sole measurable lesion Surgery : Not specify Other : No concurrent anticoagulant therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2001</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>